HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir + lamivudine in the maintenance DOLULAM pilot study

The Journal of Antimicrobial Chemotherapy
Charlotte CharpentierJacques Reynes

Abstract

The DOLULAM study assessed the efficacy of dolutegravir + lamivudine dual therapy to maintain virological suppression in heavily treatment-experienced HIV-1-infected adults. No virological failure occurred during the first year of the dual therapy. A virological substudy was conducted to assess the prevalence of M184I/V mutations at dual therapy initiation using historical DNA/RNA genotypes and baseline DNA genotype obtained by next-generation sequencing (NGS). HIV-1 RT sequences were obtained from DNA and/or historical RNA using Sanger technology. HIV-1 DNA RT and integrase NGS was performed using Illumina® technology. Among the 27 patients enrolled in the DOLULAM study, historical HIV DNA and RNA Sanger sequences were available in 14 and 18 patients, respectively. At the initiation of DOLULAM, DNA NGS genotypes showed that 45% and 21% of the patients harboured minority resistant variants (MRV) in RT and integrase, respectively. Combining all available genotype data, an M184I/V was observed in 17 of 27 (63%) of the patients. Most M184V were detected in historical RNA genotypes (n = 8 of 11), whereas M184I were exclusively detected in DNA genotypes (n = 10, including 7 as MRV). Ten patients displayed defective viral genomes in ...Continue Reading

References

Nov 9, 2010·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Karin J MetznerHauke Walter
Jan 29, 2016·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Eve TodescoLaurence Morand-Joubert
Jun 12, 2016·The Journal of Antimicrobial Chemotherapy·C KatlamaA-G Marcelin
Feb 6, 2017·The Lancet. HIV· The Lancet Hiv
Mar 24, 2017·The Journal of Antimicrobial Chemotherapy·L AssoumouUNKNOWN ANRS AC-11 Resistance Study Group

❮ Previous
Next ❯

Citations

Sep 9, 2019·Current Infectious Disease Reports·Neha Sheth PanditSarah M Michienzi
Feb 20, 2020·The Journal of Antimicrobial Chemotherapy·Josephine BriceSidonie Lambert-Niclot
Feb 24, 2018·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Romina QuerciaDaniel Kuritzkes
Aug 24, 2018·The Journal of Antimicrobial Chemotherapy·Narjis BoukliLaurence Morand-Joubert
Mar 19, 2021·The Journal of Antimicrobial Chemotherapy·Santiago Jiménez de OryUNKNOWN Paediatric Cohort of the Spanish National AIDS Network (CoRISpe and CoRISpe-FARO)
Oct 16, 2021·The Journal of Antimicrobial Chemotherapy·Colin DeschanvresUNKNOWN Dat’AIDS Study Group
Dec 7, 2021·International Journal of Antimicrobial Agents·Daniele ArmeniaUNKNOWN PRESTIGIO Registry Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.